Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation

27 Aug 2025

Abstract excerpt

Anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) are both effective drugs for graft-versus-host disease (GvHD) prophylaxis, but their combined use remains underexplored. We conducted a retrospective analysis of 582 patients with haematological malignancies who underwent unrelated donor transplantation with Status GvHD prophylaxis consisting of low-dose ATG (2 mg/kg) and PTCy over a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Hematopoietic Stem Cell Transplantation
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40859738
DOI: 10.1111/bjh.70124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationPMID 40859738Read ↗

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.Semantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideSemantic proximity Read ↗

Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantationSemantic proximity Read ↗

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA MatchSemantic proximity Read ↗

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplantSemantic proximity Read ↗

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsSemantic proximity Read ↗

The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders.Semantic proximity Read ↗

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.Semantic proximity Read ↗

Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficienciesSemantic proximity Read ↗

Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial.Semantic proximity Read ↗

Abatacept-based Graft-Versus-Host-Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant: Single Center Experience in a High-Risk CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.